Is your workout routine good enough? Don't follow social media blindly for weight loss strategies. The talk test is a way to measure the intensity of your workouts. Watch this report to know more.

The Good Life: Is your workout routine good enough? Don't follow social media blindly

China's Coronavac vaccine was 67 per cent effective at preventing symptomatic Covid-19 and 80 per cent at preventing death, according to real-life results unveiled on Friday from Chile's inoculation campaign.&nbsp;

"These figures should convey peace of mind to the country," Health Minister Enrique Paris told journalists as he announced the outcome of two months' of vaccination in Chile, in February and March.&nbsp;

The results were obtained from a comparison between people who were fully vaccinated, partly vaccinated with one dose, and non-vaccinated, a sample size of some 10.5 million in total, in the country that has led the pack with its vaccine rollout.&nbsp;

They also showed the vaccine was 85 per cent effective at preventing hospitalisation with serious coronavirus symptoms, and 89 per cent at preventing intensive care admissions.&nbsp;

Chile's government wants to inoculate 80 per cent or 15.2 million of its population. It is far ahead in Latin America, and has one of the most advanced vaccine campaigns in the world. &nbsp;

As of Friday, the country had succeeded in giving at least one vaccine dose to 7.6 million people, and both doses to more than five million, about a third of the target population.&nbsp;

It kicked off its campaign on Christmas Eve last year with medical personnel, followed by the wider population from February, starting with older citizens.&nbsp;

Coronavac, produced by Chinese firm Sinovac, made up 86.9 per cent of Chile's vaccine arsenal, with the remainder receiving the Pfizer/BioNtech jab.&nbsp;

Most of those who got it in February and March were over 60 years old, the category of people most vulnerable to serious symptoms.&nbsp;

The results were unveiled as Chile, as much of South America, recorded a marked uptick in infections. It reported a record number of confirmed new cases of more than 9,000 in one day.&nbsp;

Most of Chile's population was placed under lockdown at the end of last month.&nbsp;

Trial results with Coronavac in Brazil had shown efficiency of about 50 per cent in preventing symptomatic infection.&nbsp;

The Chile results come from one of the first studies in real-life conditions.&nbsp;

Coronavac is a traditional type of vaccine, using inactivated coronavirus to trigger immunity.&nbsp;

China's Coronavac vaccine was 67 per cent effective at preventing symptomatic Covid-19 and 80 per cent at preventing death, according to real-life results unveiled on Friday from Chile's inoculation campaign.

China's Coronavac vaccine was 67 per cent effective at preventing symptomatic Covid-19 and 80 per cent at preventing death, according to real-life results unveiled on Friday from Chile's inoculation campaign. "These figures should convey peace of mind to the country," Health Minister Enrique Paris told journalists as he announced the outcome of two months' of vaccination in Chile, in February and March. The results were obtained from a comparison between people who were fully vaccinated, partly vaccinated with one dose, and non-vaccinated, a sample size of some 10.5 million in total, in the country that has led the pack with its vaccine rollout. They also showed the vaccine was 85 per cent effective at preventing hospitalisation with serious coronavirus symptoms, and 89 per cent at preventing intensive care admissions. Chile's government wants to inoculate 80 per cent or 15.2 million of its population. It is far ahead in Latin America, and has one of the most advanced vaccine campaigns in the world. As of Friday, the country had succeeded in giving at least one vaccine dose to 7.6 million people, and both doses to more than five million, about a third of the target population. It kicked off its campaign on Christmas Eve last year with medical personnel, followed by the wider population from February, starting with older citizens. Coronavac, produced by Chinese firm Sinovac, made up 86.9 per cent of Chile's vaccine arsenal, with the remainder receiving the Pfizer/BioNtech jab. Most of those who got it in February and March were over 60 years old, the category of people most vulnerable to serious symptoms. The results were unveiled as Chile, as much of South America, recorded a marked uptick in infections. It reported a record number of confirmed new cases of more than 9,000 in one day. Most of Chile's population was placed under lockdown at the end of last month. Trial results with Coronavac in Brazil had shown efficiency of about 50 per cent in preventing symptomatic infection. The Chile results come from one of the first studies in real-life conditions. Coronavac is a traditional type of vaccine, using inactivated coronavirus to trigger immunity.

China's Coronavac 80% effective at preventing Covid deaths: Chile results 

United Nations targets for HIV testing and treatment may seem expensive at first but are very cost-effective way to boost the survival rate in the long run. 
 
According to a research at the Massachusetts General Hospital (MGH), the University of Cape Town and the Yale School of Public Health, which estimated the likely impact of the so-called &quot;90-90-90&quot; program, concluded that the program is an economical way to increase survival, reduce the number of children orphaned by HIV, and contain the global AIDS epidemic. 
 
&quot;Based on our findings, there is nothing overstated about the suggestion that 90-90-90 could lay the foundation for a healthier, more just and equitable world for future generations,&quot; says Rochelle P. Walensky, of the MGH Division of Infectious Disease, who led the study that will appear in the May 31 online edition of Annals of Internal Medicine. 
 
&quot;Yes it would be very expensive, but it would be worth every penny&quot;, said Walensky Launched in September 2014 by the Joint United Nations Programme on HIV/AIDS (UNAIDS), the 90-90-90 program has three key objectives - diagnosing 90 percent of HIV-infected persons worldwide; linking 90 percent of identified cases to antiretroviral therapy (ART); and achieving virologic suppression among 90 percent of ART recipients. 
 
The program`s overall goal is achieving viral suppression - reducing the viral load to an undetectable level - among 73 percent of HIV-infected persons worldwide by 2020, a marked improvement from current estimates of 24 percent.Critics have expressed concern that successful implementation of 90-90-90 would require unprecedented cash infusions from donor organizations such as the President`s Emergency Plan for AIDS Relief, the Global Fund, and the World Bank.Countering this concern, study`s co-author Linda-Gail Bekker, notes, &quot;Recent funding from these sources has been flat. Our goal for this study was to provide donors and partner countries with pragmatic estimates of what it will cost and what return they can expect by investing in 90-90-90.&quot; 
 
Publication of the study coincides with a June 8-10 United Nations meeting of world leaders, HIV program implementers, government representatives and other key stakeholders to solidify a plan to put an end to the global AIDS epidemic by 2030.The research has been published in Annals of Internal Medicine.

U.N. program for battling AIDS is expensive but cost effective in the long run and boosts survival rate.

United Nations targets for HIV testing and treatment may seem expensive at first but are very cost-effective way to boost the survival rate in the long run. According to a research at the Massachusetts General Hospital (MGH), the University of Cape Town and the Yale School of Public Health, which estimated the likely impact of the so-called "90-90-90" program, concluded that the program is an economical way to increase survival, reduce the number of children orphaned by HIV, and contain the global AIDS epidemic. "Based on our findings, there is nothing overstated about the suggestion that 90-90-90 could lay the foundation for a healthier, more just and equitable world for future generations," says Rochelle P. Walensky, of the MGH Division of Infectious Disease, who led the study that will appear in the May 31 online edition of Annals of Internal Medicine. "Yes it would be very expensive, but it would be worth every penny", said Walensky Launched in September 2014 by the Joint United Nations Programme on HIV/AIDS (UNAIDS), the 90-90-90 program has three key objectives - diagnosing 90 percent of HIV-infected persons worldwide; linking 90 percent of identified cases to antiretroviral therapy (ART); and achieving virologic suppression among 90 percent of ART recipients. The program`s overall goal is achieving viral suppression - reducing the viral load to an undetectable level - among 73 percent of HIV-infected persons worldwide by 2020, a marked improvement from current estimates of 24 percent.Critics have expressed concern that successful implementation of 90-90-90 would require unprecedented cash infusions from donor organizations such as the President`s Emergency Plan for AIDS Relief, the Global Fund, and the World Bank.Countering this concern, study`s co-author Linda-Gail Bekker, notes, "Recent funding from these sources has been flat. Our goal for this study was to provide donors and partner countries with pragmatic estimates of what it will cost and what return they can expect by investing in 90-90-90." Publication of the study coincides with a June 8-10 United Nations meeting of world leaders, HIV program implementers, government representatives and other key stakeholders to solidify a plan to put an end to the global AIDS epidemic by 2030.The research has been published in Annals of Internal Medicine.

UN''s ''90-90-90'' program may cost-effectively battle AIDS

effective

Effective, News on Effective, stories on Effective, articles on Effective, Effective stories at Wion, Effective news, Effective latest news